Objectives: To compare patency and complication rates of polytetrafluoroethylene (PTFE) 
Introduction
For the construction of a vascular access for haemodialysis, several biological and synthetic materials have been introduced. Polytetrafluoroethylene (PTFE), which was introduced by Baker in 1976, is now the most commonly used material for these so-called bridge grafts. 1 The cumulative secondary patency rates of PTFE vary from 60-87% after 1 year and 43-69% after 3 years. 28 Beside stenosis and thrombosis, infection is a major cause of morbidity and even mortality in patients with PTFE grafts, with reported rates from 8.5 up to 35%. 4"6' 8-11 In 1969, May et al. were the first to describe the use of saphenous vein for the creation of a bridge graft. 12 The relative unavailability of the autologous saphenous vein has prompted the use of * Please address all correspondence to: B. C. Eikelboom, Department of Surgery, University Hospital Utrecht, P.O. Box 85500, 3508 GA Utrecht, The Netherlands. -{ Members of the SMASH study group are listed in the appendix. fresh or preserved homologous vein grafts. 13 ' 14 Later this led to industrially prepared and commercially available denatured homologous vein (DHV) grafts. 15 In 1983 we started to use denatured homologous vein grafts for vascular access surgery in our hospital, and it became the material of first choice for this purpose. In a retrospective study we evaluated the use of 195 DHV grafts as conduit for haemodialysis access. 16 The primary and secondary patency rates were comparable with the results of PTFE in literature. 17 ' 18 In contrast to PTFE grafts, the infection rate in DHV grafts was very low (2.6%) and all infected grafts could be salvaged by bypassing the infected area, with no further complications. Because of the potential clinical relevance, this prospective study was undertaken to compare patency and complication rates of PTFE and DHV grafts for chronic haemodialysis in a prospective randomised trial. We hypothesised comparable patency rates but lower rate and limited extent of infection in DHV grafts compared to PTFE grafts.
Patients and Methods
A prospective randomised multicentre trial was conducted between September 1994 and April 1997. One university hospital, six general hospitals and one unit for home dialysis participated in this study.
Patients in whom a Brescia-Cimino fistula failed or could not be constructed and patients who had previously undergone secondary access surgery were eligible. The study was approved by the Ethics Committee of the hospitals concerned, and informed consent was obtained from each patient. In each hospital the DHV grafts and the PTFE grafts were randomly assigned to the patients by means of tables of random numbers generated by computer.
The denatured homologous vein grafts (Varivas®-Medicor, The Netherlands) were produced according to the method described by BonnaudJ 5 Saphenous vein stripped during varicose vein surgery is collected in vials containing 0.01% chlorohexidine solution. After storage at 4 °C for at least 4 weeks in this solution, which destroys antigenicity, the preparation procedure is undertaken. For the production the best vein parts are selected. Quality selection criteria are: (1) regularity and length of the vein segment; (2) the size of the kmer vessel diameter from 5 to 8 ram; and (3) the macroscopic appearance of the vascular wall. Side branches are ligated using 5 x 0 prolene and, to acquire a useful length of the prosthesis, shorter segments are anastomosed with 6 x 0 prolene. A leakage test is performed using isotonic saline solution under 200 mmHg pressure. Finally the prosthesis, maintained in position by a glass rod through the lumen, is inserted in a stoppered glass cylinder containing 0.02 g chloramphenicol per 100 ml isotonic saline solution. The PTFE graft was mostly (91%) a 6 mm graft, either standard PTFE (IMPRA® or Gore-tex®) or stretch-PTFE (Gore-tex®).
Patient characteristics, the details of the construction, and the use of drugs were registered. Prospectively, complications and interventions were monitored including thrombotic events, and subsequent intervention, and elective interventions to prevent thrombosis. Infection was defined as evidence of local inflammation needing systemic antibiotics and/or surgical intervention. Additionally, other complications requiring intervention including stenosis, aneurysm, steal syndrome, and bleeding, were recorded. Aneurysms were corrected surgically when they were clinically judged potentially harmful for the patient or for the graft function. For sample size calculations, we used the intervention rate per patient-year as the primary end-point. With at least 60 patients in both trial arms, we were able to estimate a difference of 0.4 intervention per patient per year (~=0.05, [3 = 0.20) . Patients were followed until definite failure of the graft, or otherwise to the end of the study period.
Patency rates, complication rates, and intervention rates of PTFE and DHV were compared. The effect of diabetes mellitus, clinically apparent vascular disease (that is a history of myocardial infarction, angina pectoris, cerebral or peripheral vascular disease), age above 60 years (median age), on patency rates was evaluated. The relationship between patency rates and the site of graft creation and the number of previous grafts was also assessed.
Data Analysis
Primary patency rate was defined as the percentage of grafts that functioned well without any surgical or catheter intervention after implantationJ 9 Primary assisted patency was defined as the percentage of grafts that functioned well after surgical or catheter intervention to prevent graft failure. 2° Secondary patency was defined as those remaining patent after elective intervention or intervention for graft failure. I9 The incidence rate was defined as the number of complications or interventions per patient-year.
Cumulative incidence was used for the calculation of patency rates with Kaplan-Mei,er analysis. Patients who died, who were lost to follow-up, who were transplanted, or who were withdrawn alive, were censored. Differences in the patency rates were tested with Log-rank test. The Cox proportional hazards survival analysis was used to assess the effect of risk factors on patency rates. Because complications could occur and recur within one patient, incidence rates per patient-year were calculated. Differences between incidence rates of complication were calculated with Poisson regression analysis. Around the estimates 95% confidence limits were calculated. A p value <0.05 was considered significant.
Results
One hundred and thirty-one patients were enrolled. Sixty-three DHV grafts and 68 PTFE grafts were implanted in 60 males and 71 females. There were 108 loop forearm grafts, 17 straight forearm grafts, three Numbers indicate number of patients, unless indicated otherwise. None of the demographic characteristics showed a significant difference between the groups. (DHV = denatured homologous vein, PTFE = polytetrafluoroethylene, py = patient year).
loop upper arm grafts and two loop thigh grafts (Table   1) . Sixty-nine (53%) patients received a graft because of failure of their Brescia-Cimino fistula, 24 (18%) because of failure of their secondary access and in 38 (29%) patients primary creation of a Brescia-Cimino fistula was not possible. The mean follow-up was 313 days for DHV (range 1-771) and 339 (3-909) days for PTFE. The total follow-up was 54.1 patient-years for DHV and 63.1 patient-years for PTFE. During this study 18 patients (29%) died, eight DHV (13%) and 10 PTFE (15%). In both the DHV and PTFE groups three patients underwent a successful kidney transplantation. Primary patency was not statistically different in the two groups. Cumulative patency at 6, 12 and 18 months was 51%, 30% and 22%, respectively, for DHV and 52%, 40% and 28%, respectively, for PTFE. Primary assisted and secondary patency was also similar. At 6, 12 and 18 months primary assisted patency was 65%, 40% and 32%, respectively, for DHV, 57%, 45% and 34%, respectively, for PTFE. Secondary patency was 80%, 63% and 54%, respectively, for DHV, 71%, 63% and 63%, respectively, for PTFE. Only 15 (24%) DHV and 16 (24%) PTFE grafts functioned without any complications throughout the study period. The most frequent complication was thrombosis, a total of 75 thrombotic events (1.39 per patient-year (py)) occurred in 35 (56%) patients with a DHV graft and 78 (1.24 per py) in 36 (53%) patients with a PTFE graft ( Table 2) . When all the first episodes of thrombosis in every patient were analysed, the proportion of early thrombosis (within 24h) was 8/35 (23%) for DHV and 4/36 (11%) for PTFE. After 1 week this was 11/35 (31%) for DHV and for PTFE this was still 4/36 (11%). The hazard ratio for thrombosis was 0.87 (95% CI 0.55-1.40) for PTFE. Most of the thrombotic episodes could be salvaged by either surgical or radiological intervention. However, 21 events in the DHV group (0.39 per patient-years) and 17 (0.27 per py) in the PTFE group were beyond repair. Infection was the more frequent complication in PTFE grafts. A total of nine infections were seen in nine (14%) patients with DHV, whereas 21 infections in 20 Eur J Vasc Endovasc Surg Vol 16, August 1998 (29%) PTFE grafts were seen (rate ratio: 2.0, 95% CI 0.9-4.4, p = 0.08) ( Table 3) . Of the total of 30 episodes of infection, 14 occurred before first needling of the graft. In the DHV group all infections but one could be salvaged with systemic antibiotics. In contrast, surgical intervention was necessary in nine PTFE grafts (rate ratio: 11.1, 95% CI 1.5-85.2, p=0.02) of which two could be salvaged, two were excised after one or more operations, and five were excised as primary therapy. Two patients died from septic problems subsequent to a graft infection (both grafts were excised).
The indications for all interventions, both curative and elective, performed to maintain graft patency are summarised in Table 4 . The interventions concerning the implantation of a new graft because of failure beyond repair are not included. Beside the difference in intervention rate for infection, the difference in intervention rate for aneurysms was also significant. Aneurysms necessitating surgical revision occurred more frequently in DHV grafts. Of five false and four true aneurysms, seven were salvaged by excision or ligation of the involved area and two grafts were replaced by a new graft. Two PTFE grafts with false aneurysms were salvaged by surgical revision (rate ratio: 0.19, 95% CI 0.04-0.88, p=0.03). No major complications were seen in grafts with an aneurysm, neither before nor after surgical revision. Overall, 97 interventions (1.79 per py) were performed in 48 DHV grafts and 101 (1.60 per py) in 52 PTFE grafts. A vascular disorder, diabetes mellitus or a higher age (older than 60 years) did not show a significant higher relative risk for complications. No difference was seen in the patency or complication rate of a patient's first versus second or third graft. The secondary patency Number of events and number of patients are indicated. (DHV = denatured homologous vein, PTFE = polytetrafluoroethylene, py = patient year). * p = 0.08, ** p = 0.02. Number of events and number of patients are indicated. (DHV = denatured homologous vein, PTFE = polytetrafluoroethylene). * p =0.02, ** p = 0.03.
was significantly worse in straight forearm grafts, compared to the looped forearm grafts (p = 0.01). The relative risk for a straight graft was 2.5 (95% CI 1.2-5.2).
Discussion
In this prospective randomised trial we found no differences in patency rates between DHV and PTFE grafts. Complication rates were comparable, except for the need for intervention for aneurysms, which occurred more frequently in DHV grafts, and the need for intervention for infection, which was seen more frequently and more extensively in PTFE grafts. This study clearly underscores the existing evidence that access related morbidity is extensive. In a period of approximately 2.5 years, 131 patients were enrolled in this multicentre study. We found a 1-year secondary patency rate of 63% for DHV. This is somewhat lower than the 76% in our retrospective analysis, 16 but is comparable with the results of Gecim et al. 21 They reported a secondary patency of 66.4% in a prospective study of 36 DHV grafts. Bonnaud et al. described their 20 years' experience in secondary access surgery. They implanted 234 self-made and manufactured DHV grafts and 162 PTFE grafts. 22 These authors found a higher 1-year secondary patency rate for DHV (+83%) compared to our study, but they also found better results for PTFE grafts (+ 78% at 1 year).
The most frequent complication was thrombosis. In more than half of all patients at least one episode of thrombosis occurred within the study period. This resulted in incidence rates of 1.39 and 1.24 events per patient-year, despite of 0.44 and 0.29 elective interventions per patient-year meant to prevent thrombosis, for DHV and PTFE, respectively. Compared with literature data the rates of thrombosis are higher than reported by Besarab et aL 23 and Schwab et aI., 24 but comparable to the results of Beathard. 25 Of note is the finding of a higher thrombosis rate within the first week of construction in DHV grafts compared to PTFE graft. Conceivably this might have been caused by the higher risk of twisting the DHV graft during implantation.
The difference in the overall infection rate of DHV and PTFE was not significant. However, the number of cases in which surgical intervention for these infections was done was significant(p = 0.02). In the DHV group only one patient needed surgical intervention, and the graft was salvaged. This finding is comparable with the 2.6% infection needing surgical intervention in our retrospective analysis, 16 and with the 2% serious infections described by Bonnaud et a/. 22 In contrast, surgical intervention was necessary in nine PTFE grafts, of which only two could be salvaged. Several authors described good salvage results in PTFE grafts, using one-or two-stage segmental bypasses, 4'11 '26 though others removed most of the infected grafts in their patients. 3' 6' 27' 28 Two patients with a PTFE graft died after a graft infection. In both patients an effort was made to salvage the graft by surgical intervention, but eventually both grafts were excised. Approximately half of all episodes of infection occurred before first needling of the graft, and therefore should be considered as per-or postoperative complications. The number of operation related infections is high in comparison with most of the literature, 4' 29' 3° although for PTFE graft insertion an incidence of infection as high as 15% has been described. 4 The standard antibiotic protocol included a single dose of either cephalosporin or flucloxacillin, 30 min before the operation. However, not all patients received antibiotics prior to surgery. Eleven grafts, six DHV and five PTFE, were implanted without prophylactic antibiotics prior to operation. However, in these DHV grafts only one infection occurred (after 87 days), and in the PTFE grafts also one infection occurred (after 145 days). Thus, a relation with the absence of prophylactic antibiotics is unlikely. The use of prophylactic antibiotics has been shown to be valuable in preventing infection, though others have not been able to confirm this finding. 10,26,31
We were not able to find a relationship between the use of drugs, such as aspirin and warfarin, and graft function, possibly because the number of patients in this study was too small. 32~4 Neither were we able to find a relationship between diabetes mellitus, clinically apparent vascular disease, or age >60 years and graft function. The choice of the donor artery for the construction of the graft did make a difference. Of all grafts, 92% were placed in the forearm, usually in a looped configuration (brachial artery) and in 17 cases as straight grafts (radial artery). The patency was significantly worse in these straight forearm grafts, compared to the looped forearm grafts. Better results for straight grafts compared to looped grafts have been described, 35 but most authors have described worse results for straight grafts. 4'6'36 It is conceivable that the flow in a graft anastomosed with the radial artery is lower than in a graft anastomosed with the larger brachial artery. 37 Furthermore, in our study, most of the straight grafts were converted from Brescia-Cimino fistulas and not initially created as a secondary access. In most of these straight grafts the anastomosis was created with an arterialised vein in the wrist and therefore the graft has in fact a third anastomosis, which also may affect graft flow. Both factors may influence the patency of straight grafts, since it has been shown that a low graft flow increases the risk for graft thrombosis. 3°'3s '39 In conclusion, it is clear that none of the available graft materials offer optimal performance. Thrombosis and infection remain the main complications. Our study shows that infection occurs less frequently in DHV compared to PTFE, and that these infections are usually limited. However, intervention for aneurysms occurs more frequently in DHV grafts. Otherwise, the two materials do not show important differences.
